Evolving CMC Strategies To Enable Next-Gen ADCs

Antibody-drug conjugates (ADCs) are evolving beyond conventional constructs to incorporate novel payloads, advanced linker technologies, and site-specific conjugation. These innovations demand greater consideration for all aspects of CMC, from manufacturability to linker design, analytical characterization, and regulatory alignment.

In this on-demand Bioprocess Online Live hosted by Tyler Menichiello, leading experts in the space discuss how innovative ADC companies need to evolve their CMC strategies to support the development of these next-generation molecules. This engaging Q&A features CrossBridge Bio’s CEO and co-founder, Michael Torres, Ph.D., and acting CTO, Morris Rosenberg, Ph.D., as well as Borys Shor, Ph.D., an advisor to OS Therapies and director at Manhattan BioSolutions.

This recording is available to watch for free thanks to the event sponsor, Cytiva.